Across these studies, pamiparib monotherapy resulted in an ORR of 27.3% in a phase 1a/b dose‐escalation/dose‐expansion study of patients with advanced or metastatic solid tumors24; 64.6% among patients with BRCA1/2‐mutated platinum‐sensitive ovarian cancer and 31.6% among patients with BRCA1/2‐mutated platinum‐resistant ovarian cancer in a phase 2 study25; and 38.2% among triple‐negative breast cancer (TNBC) patients with germline BRCA1/2 mutations in a phase 2 study.26 Here, BRCA1 is linked to ovarian cancer.